Quercetin

Quercetin

SCHEMBL5083988

O=C(/C=C/c1ccc(O)cc1)c1ccc(O)cc1O.O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.65
KMT2A Q03164 11/20 0.65
CYP3A4 P08684 9/20 0.65
CYP2C9 P11712 8/20 0.65
HSD17B10 Q99714 8/20 0.65
ALOX15 P16050 7/20 0.65
CYP1A2 P05177 7/20 0.65
KDM4E B2RXH2 7/20 0.65
APP P05067 7/20 0.65
MAPT P10636 7/20 0.65
TP53 P04637 6/20 0.65
AKR1B1 P15121 6/20 0.65
RECQL P46063 6/20 0.65
TDP1 Q9NUW8 6/20 0.65
HPGD P15428 6/20 0.65
HDAC6 Q9UBN7 6/20 0.65
XDH P47989 6/20 0.65
CYP2C19 P33261 5/20 0.65
LMNA P02545 5/20 0.65
DAPK1 P53355 5/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetin SCHEMBL444562 0.83 MEN1 (0.67) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL25221565 0.83 MEN1 (0.67) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL288466 0.82 MEN1 (0.92) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Kaempferol SCHEMBL5090719 0.82 MEN1 (0.67) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL28196529 0.82 MEN1 (0.97) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Kaempferol SCHEMBL23070109 0.81 MEN1 (0.73) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL31507620 0.81 MEN1 (1.00) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL19723 0.81 MEN1 (1.00) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL118425 0.81 MEN1 (1.00) MEN1KMT2ACYP3A4CYP2C9HSD17B10
Quercetin SCHEMBL29723041 0.81 MEN1 (1.00) MEN1KMT2ACYP3A4CYP2C9HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885CYP3A4 1589/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN MEN1 3687/4885KMT2A 1354/4885CYP3A4 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.